Kymera develops drugs that degrade disease-causing proteins.
Kymera Therapeutics, Inc. (KYMR) is expected to report earnings on Tuesday, November 3, 2026, after the close. Estimated release time 07:10 ET. Consensus EPS estimate is $-1.25.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | FY2026 Q2 | $-0.71 | $-0.62 | +13.0% | $65.00M |
| 2026-04-30 | FY2026 Q1 | $-0.89 | $-0.71 | +20.2% | — |
| 2025-08-11 | FY2025 Q2 | $-0.83 | $-0.95 | -14.5% | $11.48M |
| 2025-05-09 | FY2025 Q1 | $-0.92 | $-0.82 | +10.9% | $22.10M |
| 2025-02-27 | FY2024 Q4 | $-0.76 | $-0.88 | -15.8% | $7.39M |
| 2024-08-07 | FY2024 Q2 | $-0.69 | $-0.58 | +15.9% | $25.65M |
| 2024-05-02 | FY2024 Q1 | $-0.73 | $-0.69 | +5.5% | $10.29M |
| 2024-02-22 | FY2023 Q4 | $-0.44 | $-0.25 | +43.2% | $47.88M |
KYMR has beaten consensus EPS in 6 of its last 8 reported quarters.
Highlights from KYMR's Aug 5 report: EPS of -$0.62 — a beat vs the -$0.71 estimate (+13%); revenue of $65M — a big beat vs the $33M consensus (+98%). Focus now shifts to degrader pipeline readouts.
See KYMR on the live calendar →